Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Cedars-Sinai's groundbreaking online registry improves participation in clinical research

Research for Her, Cedars-Sinai's groundbreaking online registry that matches women with research studies and clinical trials, enrolled study participants more quickly when compared with traditional paper-based registries, according to new research published in the journal Gynecologic Oncology.

14 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

Molecular cancer expert David Livingston named recipient of Basser Global Prize

The Basser Center for BRCA at Penn's Abramson Cancer Center has announced the recipient of its third annual Basser Global Prize. The honor will go to molecular cancer expert David Livingston, MD, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, and deputy director of the Dana-Farber/Harvard Cancer Center.

10 Jul 2015

Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

The National Cancer Institute has awarded Huntsman Cancer Institute at the University of Utah its Comprehensive Cancer Center status, the highest designation possible.

9 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.

7 Jul 2015

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.

6 Jul 2015

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.

2 Jul 2015

PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.

30 Jun 2015

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

With more than 800,000 new cases of cancer among women in the United States expected this year, according to the American Cancer Society, almost everyone is touched by the disease.

27 Jun 2015

No overall survival benefit for bevacizumab in ovarian cancer

Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial.

26 Jun 2015

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America.

25 Jun 2015

VolitionRx teams up with market access consulting agencies to support access of NuQ cancer tests across Europe

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has established partnerships with two prominent market access consulting agencies, DecideumCogentia and MedPass International, to support market access of its NuQ® cancer tests across Europe.

24 Jun 2015

Dr. Maurizio D'Incalci to receive Pezcoller-Prodi Award in Scientific Career

Dr. Maurizio D'Incalci, MD, Ph.D., will receive an award in recognition of his scientific career at the new Special Conference on Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic organized by the European Association of Cancer Research, the American Association of Cancer Research and the Italian Cancer Society and that will be held in Florence, Italy, June 20-23.

23 Jun 2015

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015.

22 Jun 2015

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients.

18 Jun 2015

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.

17 Jun 2015

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

In a special issue of Immunotherapy, leading experts provide in-depth review of innovative strategies that may further the success of adoptive cell immunotherapy as a cancer treatment. Adoptive cell immunotherapy (ACT) has proven successful in clinical trials against certain types of melanoma and leukemia. The journal reviews new strategies to address the challenges of extending these effects to a wider range of tumor types.

17 Jun 2015

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

New research by an international team including Keck Medicine of USC scientists is bringing the origins of ovarian cancer into sharper focus.

16 Jun 2015

Ludwig Cancer Research announces opening of new branch in Lausanne, Switzerland

Ludwig Cancer Research announced today that it is opening a new Branch in Lausanne, Switzerland. The Branch will be focused primarily on applied cancer immunology and the design of novel molecular and cell-based immunotherapies. It will also develop technologies enabling the efficient, safe application of those therapies to as many patients as possible.

12 Jun 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Cedars-Sinai's groundbreaking online registry improves participation in clinical research

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Molecular cancer expert David Livingston named recipient of Basser Global Prize

Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

No overall survival benefit for bevacizumab in ovarian cancer

Larrea Biosciences merged into Gordian Holdings

VolitionRx teams up with market access consulting agencies to support access of NuQ cancer tests across Europe

Dr. Maurizio D'Incalci to receive Pezcoller-Prodi Award in Scientific Career

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Nanoplatform technology that detects early stages of cancer receives U.S. patent

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

Ludwig Cancer Research announces opening of new branch in Lausanne, Switzerland

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in